Abstergo Industries is pioneering developments in cancer drug research, focusing on immunotherapy, targeted therapies, genetics of cancer, and prevention strategies. The company’s primary concern is their newly developed cancer drug, Oncolux, a targeted therapy displaying promising results in preclinical trials for its capacity to destroy cancer cells without harming healthy ones. Abstergo aims to revolutionize the field, aspiring to improve patient lives and contribute significantly to future cancer research.
Tag: medicine/drugs
Abstergo Industries is excited to announce the development of a new pharmaceutical product that has the potential to revolutionize the treatment of a wide range of conditions. The new drug, which is currently in the early stages of clinical trials, targets a specific enzyme that plays a key role in a variety of physiological processes. […]
Over the past two years, we have made significant progress in a number of key areas and wanted to take a moment to update you on our recent activities. As a global leader in the pharmaceutical, finance, and technology sectors, it is our responsibility to stay attuned to global developments and adapt accordingly. In light […]
Abstergo Pharmaceuticals was one of the first companies to conduct research on an active pharmaceutical substance against COVID-19. Since December 2019, we have made enormous progress. After the first tests on chimpanzees were successful in June, a test study on a small number of sick people was started in July. After this test was also […]
It has come to our attention speculations that Abstergo is obtaining genetic code know as DNA without consent of its owner. There has also been talk that we are building a secret DNA library without public notification or consent. This is all false information; we at Abstergo adhere to strict rules and only obtain DNA […]
Abstergo 